These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 7708616)

  • 21. New drugs: which should be included in the formulary? Epilepsy: all new drugs should be included.
    Pierre-Louis SJ
    Arch Neurol; 2000 Feb; 57(2):272-3. PubMed ID: 10681089
    [No Abstract]   [Full Text] [Related]  

  • 22. Antiepileptic drugs in children in developing countries: research and treatment guideline needs.
    Farkhondeh M; Hill SR; Cross JH; Dua T
    Epilepsia; 2009 Nov; 50(11):2340-3. PubMed ID: 19744112
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New advice on switching antiepileptic drugs might be a false economy.
    Holmes E; Plumpton C; Duerden M; Marson T; Hughes D
    BMJ; 2013 Dec; 347():f7471. PubMed ID: 24342221
    [No Abstract]   [Full Text] [Related]  

  • 24. Problem of managing patients with epilepsy in developing countries.
    Kuruvilla A
    Epilepsia; 1999 Oct; 40(10):1465-6. PubMed ID: 10528947
    [No Abstract]   [Full Text] [Related]  

  • 25. A comparison of surgical and medical costs for refractory epilepsy.
    Platt M; Sperling MR
    Epilepsia; 2002; 43 Suppl 4():25-31. PubMed ID: 12059998
    [No Abstract]   [Full Text] [Related]  

  • 26. Financial aspects of introduction and application of new drugs and technologies.
    Vickrey BG; Gumnit RJ
    Epilepsy Res Suppl; 1996; 11():211-6. PubMed ID: 9294738
    [No Abstract]   [Full Text] [Related]  

  • 27. Direct and indirect costs of refractory epilepsy in a tertiary epilepsy center in Germany.
    Hamer HM; Spottke A; Aletsee C; Knake S; Reis J; Strzelczyk A; Oertel WH; Rosenow F; Dodel R
    Epilepsia; 2006 Dec; 47(12):2165-72. PubMed ID: 17201718
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness of first-line antiepileptic drug treatments in the developing world: a population-level analysis.
    Chisholm D;
    Epilepsia; 2005 May; 46(5):751-9. PubMed ID: 15857443
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Drug therapy in epilepsy. New preparations are not yet the drugs of first choice].
    Tomson T
    Lakartidningen; 1996 Oct; 93(41):3557-8, 3563-5. PubMed ID: 8965512
    [No Abstract]   [Full Text] [Related]  

  • 30. Impact of nonadherence to antiepileptic drugs on health care utilization and costs: findings from the RANSOM study.
    Faught RE; Weiner JR; Guérin A; Cunnington MC; Duh MS
    Epilepsia; 2009 Mar; 50(3):501-9. PubMed ID: 19183224
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Therapeutic strategies in the choice of antiepileptic drugs.
    de Borchgrave V; Delvaux V; de Tourchaninoff M; Dubru JM; Ghariani S; Grisar T; Legros B; Ossemann M; Sadzot B; Tugendhaft P; Van Bogaert P; van Rijckevorsel K;
    Acta Neurol Belg; 2002 Mar; 102(1):6-10. PubMed ID: 12094563
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The economic implications of generic substitution of antiepileptic drugs: a review of recent evidence.
    Duh MS; Cahill KE; Paradis PE; Cremieux PY; Greenberg PE
    Expert Opin Pharmacother; 2009 Oct; 10(14):2317-28. PubMed ID: 19663636
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmaceutical Benefits Scheme restrictions on anti-epileptic drug prescribing promote unsafe and outdated practice.
    Gericke CA; O'Brien TJ
    Med J Aust; 2019 Jul; 211(2):55-57.e1. PubMed ID: 31256431
    [No Abstract]   [Full Text] [Related]  

  • 34. [The costs of epilepsy in Germany].
    Dodel R; Rosenow F; Hamer HM
    Pharm Unserer Zeit; 2007; 36(4):298-305. PubMed ID: 17623320
    [No Abstract]   [Full Text] [Related]  

  • 35. The costs of epilepsy and cost-based evaluations of anticonvulsants.
    Johnson WG
    Pharmacoeconomics; 1997 Oct; 12(4):446-59. PubMed ID: 10174311
    [TBL] [Abstract][Full Text] [Related]  

  • 36. NIH epilepsy branch trials: budgetary and practical issues.
    Jacobs MP
    Epilepsy Res Suppl; 1993; 10():239-44. PubMed ID: 8251102
    [No Abstract]   [Full Text] [Related]  

  • 37. Perampanel (Fycompa) for epilepsy.
    Med Lett Drugs Ther; 2014 Feb; 56(1435):9-10. PubMed ID: 24662975
    [No Abstract]   [Full Text] [Related]  

  • 38. The new generation of antiepileptic drugs: unresolved questions.
    Graves NM; Gidal BE; Gilliam FG
    Ann Pharmacother; 1998 Nov; 32(11):1239-43. PubMed ID: 9825094
    [No Abstract]   [Full Text] [Related]  

  • 39. Position statement on the coverage of anticonvulsant drugs for the treatment of epilepsy: what's the problem with generic antiepileptic drugs? A call to action.
    Miller JW; Anderson GD; Doherty MJ; Poolos NP
    Neurology; 2007 Oct; 69(18):1806-8. PubMed ID: 17967998
    [No Abstract]   [Full Text] [Related]  

  • 40. The renaissance of rational polytherapy: the new generation of antiepileptic medications.
    Neurology; 1995 Mar; 45(3 Suppl 2):S35-8. PubMed ID: 7898744
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.